Abstract:OBJECTIVETo investigate the imunogenicity and protective efficacy of the divalent DNA vaccine encoding the antigens MPT83 and MPT64 of Mycobacterium tuberculosis.METHODSTwo genes of the M. tuberculosis, MPT83 and MPT64, were amplified and cloned into the vector pJW4303. The vector containing the fusion gene DNA-MM and pJW4303 blank vector were transfected into CO57 cells. The expression of DNA-MM in the supernatant was detected by Western blotting. Thirty-six C57BL/6 mice were divided into 3 equal groups to be injected subcutaneously with the vector containing the fusion gene DNA-MM, pJW4303 blank vector, or bacillus of Calmette-Guerin vaccine (BCG) once a week for 3 weeks. Twelve mice were used as non-immunized controls. Blood samples were collected from the mice before and after every immunization to detect the titer of antibody by ELISA. Three weeks after the 3rd immunization 3 mice from each were killed and their spleens were taken out. The splenocytes were cultured and stimulated by the recombinant antigen to detect the concentrations of interferon (IFN)-gamma and interleukin (IL)-4. Six weeks after the 3rd immunization M. tuberculosis of the line H37Rv was injected intravenously into the mice. Eight weeks later, the mice were killed and their lungs and spleens were taken out. The tissues were cultured to calculate the numbers of M. tuberculosis.RESULTSWestern blotting showed that the CO57 cells transfected with the vector containing the fusion gene expressed DNA-MM. ELISA showed that no antibody titer was detected before immunization in every group. The titer of MPT83 and MPT64 were increased to 1:200, 1:800, and 1:6400 3 weeks after the 1st, 2nd, and 3rd immunization respectively in the divalent group, increased to 1:800 3 weeks after the 3rd immunization in the BCG group, and remained 0 at any time points in the blank vector group. The IFN-gamma titer of the divalent group was 7520 pg/ml, significantly higher than that of the BCG group (6675.6 pg/ml, P < 0.05). The IL-4 concentration was basically the same and at the ng level in all groups. After challenge of H37Rv the bacterial loading in the lung was (2.21 +/- 0.032) x 10(5) in the divalent group, one thousandth of that in the blank vector group, and one tenth of that in the BCG group.CONCLUSIONThe divalent vaccine containing the antigens MPT83 and MPT64 effectively heightens the protective efficiency of vaccine against tuberculosis.

Mycobacterium lipid components enhanced the protective efficacy of tuberculosis subunit vaccine

Protective Efficacy of Mycobacterium Tuberculosis Fusion Protein Subunit Vaccine As A Booster to Enhance BCG Primed Immunity

A Novel Liposome Adjuvant DPC Mediates Mycobacterium Tuberculosis Subunit Vaccine Well to Induce Cell-Mediated Immunity and High Protective Efficacy in Mice.

Immunogenicity and Protective Efficacy of a Fusion Protein Vaccine Consisting of Antigen Ag85B and HspX Against Mycobacterium Tuberculosis Infection in Mice

Cell wall skeleton of Mycobacterium bovis BCG enhances the vaccine potential of antigen 85B against tuberculosis by inducing Th1 and Th17 responses

DDA and BCG Polysaccharide Nucleic Acid Improved the Immunogenicity and Protective Efficacy of Tuberculosis Subunit Vaccine Against Mycobacterium Tuberculosis Infection in Mice

Subunit Vaccine Consisting Of Multi-Stage Antigens Has High Protective Efficacy Against Mycobacterium Tuberculosis Infection In Mice

[Dimo-Thylidioctyl Ammonium Bromide-Bcg Polysaccharide Nucleic Acid Adjuvant Enhanced the Immunogenicity of a Mycobacterium Tuberculosis Subunit Vaccine].

[Immunogenicity and Protection of Divalent DNA Vaccine Encoding Antigens MPT83 and MPT64 of Mycobacterium Tuberculosis].

A multistage mycobacterium tuberculosis subunit vaccine LT70 including latency antigen Rv2626c induces long-term protection against tuberculosis

A multistage protein subunit vaccine as BCG-booster confers protection against Mycobacterium tuberculosis infection in murine models

The adjuvant effects of CpG-ODN and PolyICLC in tuberculosis subunit vaccine

A Multistage Protein Subunit Vaccine As Bcg-Booster Confers Protection Against M Ycobacterium Tuberculosis Infection in Murine Models

The Combination of Mycobacterium Tuberculosis Fusion Proteins LT33 and LT28 Induced Strong Protective Immunity in Mice

Intrinsic immunogenicity of liposomes for tuberculosis vaccines: effect of cationic lipid and cholesterol

Heterologous Boosting With<i>Listeria</i>-Based Recombinant Strains in BCG-Primed Mice Improved Protection Against Pulmonary Mycobacterial Infection

More vaccine efficacy studies on the recombinant Bacille Calmette-Guerin co-expressing Ag85B, Mpt64 and Mtb8.4.

[Lc3-Lpqh Enhances the Immunoprotection of Ag85B DNA Vaccine Against Mycobacterium Tuberculosis].

Heterologous Boosting With Listeria -Based Recombinant Strains in BCG-Primed Mice Improved Protection Against Pulmonary Mycobacterial Infection.

Subunit Vaccine Candidate AMM Down‐Regulated the Regulatory T Cells and Enhanced the Protective Immunity of BCG on a Suitable Schedule

Fusion Protein Ag85B-MPT64190–198-Mtb8.4 Has Higher Immunogenicity Than Ag85B with Capacity to Boost BCG-primed Immunity Against Mycobacterium Tuberculosis in Mice